
Genesys Capital
@genesyscapital
Life sciences VC
ID: 2337010501
http://genesyscapital.com 10-02-2014 17:15:23
130 Tweet
342 Followers
64 Following


BREAKING: Our co-creation exits now totaling US$3.5B in <12 months: $FUSN to be acquired by $AZN for $2.4B Congrats to John Valliant & Fusion Pharmaceuticals team! Damian Lamb was the inaugural Chairman of the Board, from company creation through IPO. ir.fusionpharma.com/2024-03-19-Fusā¦


Good news keeps on flowing here at Genesys: Flosonics secures US$20M Series C to accelerate growth. Led by New Leaf Ventures , with participation from previous investors @ArboretumVC, Genesys Capital & iGan Partners Congrats to Joe Eibl & FloPatch | Flosonics Medical team! flosonicsmedical.com/flosonics-mediā¦



Origin Story of Fusion Pharmaceuticals $FUSN Last week Genesys portfolio company Fusion Pharmaceuticals announced its acquisition by AstraZeneca! Check out our contributions to this Canadian success story below




This week AstraZeneca completed the acquisition of Genesys portfolio company Fusion Pharmaceuticals for US$2.4B!Ā What a journey it has and we're thrilled to see Ontario becoming a global hub of excellence for radiopharmaceuticals. prnewswire.com/news-releases/ā¦


TWO Genesys co-creations make the list of Fierce's "Top 10 smartest deals in biopharma" - Inversago Pharma & Fusion Pharmaceuticals!Ā A tribute to the value of the Genesys investment thesis #madeinCanada fiercebiotech.com/biotech/smarteā¦

Big News for Profound Medical! The CMS has proposed Category 1 CPT codes for TULSA, putting its reimbursement in the same ballpark as standard of care radical prostatectomy, but with better safety outcomes. Raymond James rates as a Strong Buy. globenewswire.com/news-release/2ā¦


With Genesysā funding, Feldan aims to develop a first-in-class non-invasive intralesional treatment for basal cell carcinoma. We are very excited to be part of Feldanās ādrug delivery platformā mission and itās an excellent addition to our newest Fund. newswire.ca/news-releases/ā¦

Genesys is closing out a fantastic week at this yearās Morgan Stanley Healthcare Conference in NYC. A highlight for us was hearing Novo Nordisk's excitement about Monlunabant, acquired from Inversago Pharma last year, and its potential to change the landscape of metabolic disease!



What an achievement for Profound Medical! āTULSA to stand above all other covered prostate disease treatment modalities at Urology Level 7 reimbursement" - which speaks to the value of the TULSA system. Congrats to the Profound team! globenewswire.com/news-release/2ā¦


Congrats to Profound Medical on joining forces with Siemens Healthineers under a co-sale and co-marketing agreement! Will be exciting to watch how this partnership + attractive reimbursement drives sales in 2025 #TULSA #prostatecancer #BPH globenewswire.com/news-release/2ā¦

Team Genesys is heading for the 25th time to the #JPM25. The weather forecast looks better than the last year's & we hope that this lifts sentiments across the life sci sector Also, Genesys originated company Profound Medical will be presenting for the 1st time at JPM this year.

